Cilgavimab  (Synonyms: 西加韦单抗; AZD-1061; COV2-2130)

Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

SARS-CoV-2^[1][2]

Cilgavimab 和 Tixagevimab 能够同时结合到 SARS-CoV-2 刺突蛋白 (S) 受体结合域的不同、不重叠的表位，以有效中和病毒^[1]。
Cilgavimab 具有较强的单克隆抗体中和活性和人 ACE2 阻断活性，IC₅₀ 为 10-150 ng/mL，并能与三聚体 S2Pecto 蛋白或单体 SRBD 蛋白结合，IC₅₀ 为 0.1-10 ng/mL^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cilgavimab (200 μg/小鼠; 腹腔注射; 感染 SARS-CoV-2 前 1 h 处理) 保护小鼠免于体重减轻，减少病毒负担和肺部炎症水平^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2420563-99-9

液体

Colorless to light yellow

西加韦单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200.  [Content Brief]

  [2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449.  [Content Brief]